SAB Biotherapeutics (NASDAQ:SABS) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $3.26 and traded as high as $3.37. SAB Biotherapeutics shares last traded at $3.35, with a volume of 741,051 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SABS. Weiss Ratings upgraded SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Stock Up 3.7%

The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $304.80 million, a PE ratio of -2.58 and a beta of 0.58. The business’s 50-day moving average price is $3.26 and its 200-day moving average price is $3.68.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). As a group, equities research analysts predict that SAB Biotherapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC boosted its stake in shares of SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after acquiring an additional 5,628,533 shares in the last quarter. Seven Fleet Capital Management LP lifted its stake in shares of SAB Biotherapeutics by 47.2% in the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock valued at $2,871,000 after buying an additional 236,077 shares during the period. Affinity Asset Advisors LLC acquired a new stake in SAB Biotherapeutics during the first quarter worth about $2,202,000. Monashee Investment Management LLC acquired a new stake in SAB Biotherapeutics during the first quarter worth about $1,915,000. Finally, DV Trading LLC bought a new position in SAB Biotherapeutics during the first quarter valued at about $1,532,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.